Description: Attend if you are an organization interested in utilizing various kinds of client data to improve the whole insurance sales process, and to develop new applications. Interested parties may include distribution sales force, underwriting, claims, actuarial and finance departments within a typical insurance company, online distribution partners, health care providers and other consulting service providers. The research looks into various use cases, which are typically main issues in modeling in the insurance industry. The research also helps benchmark performance using different languages that may serve as a good reference when best to use a certain language to enhance the development cycle.

Description: Enjoy an in-depth walkthrough of the facets of the lab testing world in this webcast. The agenda will include a discussion on genetic testing, which focuses on its general background, current trends and tests in the pipeline, as well as a focus on the approaches to achieve savings in lab testing. Finally, expect to check out sample actuarial analyses that will be used to identify areas of focus in lab management. Join us and take a deeper look into lab work in the actuarial health industry.

Description: Explore SOA-sponsored research on Social Determinants of Health (SDOH) during the How Does Where You Live Impact Your Health webcast. Dive into SDOH data and modeling that will focus on cluster analysis. This will help determine the overall impact of your area's affect on your health and life. This webcast also covers an overview of the existing SDOH-related programs that may affect or intersect with health plan or provider SDOH initiatives. Discover the importance of the place you live and future impact of your overall health.

Description: At the conclusion of this session, attendees will be equipped to apply relative risk curves in their actuarial work, including the ability to examine dose-response relationships, apply population attributable fractions (PAFs), and develop customized risk models for cause-specific mortality and morbidity outcomes based on individual-level exposures to selected risk factors. These skills are becoming increasingly important as actuaries adopt novel applications of big data and dynamic health information to refine risk assessments and keep pace with global health trends.

Description: Modern actuarial work, being quite data intensive, provides many opportunities for actuaries to use the statistical skills that are part of their basic training. Furthermore, modern computing allows us to analyze vast quantities of data intensively, and each package will provide statistical 'answers' to any questions the actuary might ask of it.

Description: This session will explore recent and historical advancements in computing relevant to actuarial analysis. We will provide a comprehensive overview of the current landscape, tracing the journey of how we arrived here and how actuaries are already harnessing these innovations. This session will primarily be focused on hardware and as software programming interfaces the latter, in effect, helps accelerate code and ease of access to specialized hardware. We will also examine optimization opportunities involving the intersection of the two.

Description: Virtual - Session 1D: Pharmacy Risk Mitigation - Pricing, Programs, Pools, and Performance Guarantees

Description: Actuaries historically modeled new launches in pharmaceuticals by anticipating the expected change to the market basket. This became more complicated with the recent launches of gene and cell therapies as they address rare diseases. Rare conditions have low total member volume to study and some do not currently have a diagnosis code to identify them within claims data. Addressing this modeling challenge has been growing more important in the recent years with the number of therapies launching. What has the health care industry, and more specifically health care, done to enhance modeling and how should this be altered for the future? Additionally, historic modeling has sometimes incorporated a level of direct medical treatment cost offsets where studies have shown lower treatment costs are achievable. Can gene and cell financial modeling include cost offsets as well? And if so, what are suggested precautions or limitations to this effort?

Description: Renal disease is a very heterogenous medical condition whose end state is dialysis, a recurring cost intensive medical condition. Dialysis cost is one of the major medical cost drivers in USA. Insufficient and improper care management in the early stages of CKD (chronic kidney disease) leads to early incidence of end stage renal disease (ESRD) among CKD patients which not only leads to high medical costs, but also reflects poor health quality.

Description: Session 1F: The Math Behind The Machine - A Review of First Principles